Difference between herpes simplex virus type 1 and type 2 neonatal encephalitis in neurological outcome

Area of Science:

• Pediatric Neurology
• Infectious Diseases
• Virology

Background:

• Neonatal herpes simplex virus (HSV) encephalitis is a severe condition requiring prompt antiviral treatment.
• Understanding the long-term neurological and developmental sequelae is crucial for patient management and prognosis.
• Differentiation between HSV-1 and HSV-2 in neonatal encephalitis may impact outcomes.

Purpose of the Study:

• To assess and compare the neurological and developmental outcomes of infants treated for neonatal herpes simplex virus (HSV) encephalitis.
• To evaluate the long-term effects of acyclovir or vidarabine treatment based on HSV type (HSV-1 vs. HSV-2).

Main Methods:

• Retrospective follow-up of 24 infants treated for neonatal HSV encephalitis.
• Assessment of neurological and developmental status at 6 months to 3 years post-treatment.
• Comparison of outcomes between infants infected with HSV-1 and HSV-2.

Main Results:

• Infants with HSV-2 encephalitis showed more frequent seizures, higher cerebrospinal fluid abnormalities, and greater brain structural damage compared to HSV-1.
• All 9 infants with HSV-1 encephalitis had normal neurological outcomes at follow-up.
• Only 4 of 14 surviving infants with HSV-2 encephalitis (23%) had normal outcomes; significant morbidities included microcephaly, seizure disorders, ophthalmological defects, cerebral palsy, and mental retardation.

Conclusions:

• Systemic antiviral chemotherapy for neonatal HSV-1 encephalitis results in excellent neurological outcomes.
• Neonatal HSV-2 encephalitis is associated with high rates of severe neurological and developmental morbidity despite treatment.
• Type-specific differences in neonatal HSV encephalitis outcomes highlight the need for targeted management strategies.